These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33844588)

  • 1. What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring.
    Galindo RJ; Parkin CG; Aleppo G; Carlson AL; Kruger DF; Levy CJ; Umpierrez GE; McGill JB
    Diabetes Technol Ther; 2021 Sep; 23(9):652-660. PubMed ID: 33844588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria.
    Galindo RJ; Aleppo G; Parkin CG; Baidal DA; Carlson AL; Cengiz E; Forlenza GP; Kruger DF; Levy C; McGill JB; Umpierrez GE
    J Diabetes Sci Technol; 2024 Jul; 18(4):974-987. PubMed ID: 36524477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.
    Aleppo G; Parkin CG; Carlson AL; Galindo RJ; Kruger DF; Levy CJ; Umpierrez GE; Forlenza GP; McGill JB
    Diabetes Technol Ther; 2021 Oct; 23(10):715-725. PubMed ID: 34077674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Glucose Monitoring (CGM) Is a Tool, Not a Reward: Unjustified Insurance Coverage Criteria Limit Access to CGM.
    Kruger DF; Anderson JE
    Diabetes Technol Ther; 2021 Sep; 23(S3):S45-S55. PubMed ID: 34160300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified.
    Anderson JE; Gavin JR; Kruger DF
    Diabetes Technol Ther; 2020 Mar; 22(3):169-173. PubMed ID: 31596132
    [No Abstract]   [Full Text] [Related]  

  • 6. Addressing healthcare disparities and managed care considerations with continuous glucose monitoring.
    McAdam-Marx C
    Am J Manag Care; 2022 Jul; 28(4 Suppl):S76-S84. PubMed ID: 36007237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations.
    Forlenza GP; Carlson AL; Galindo RJ; Kruger DF; Levy CJ; McGill JB; Umpierrez G; Aleppo G
    Diabetes Technol Ther; 2022 Nov; 24(11):814-823. PubMed ID: 35763323
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous Glucose Monitoring in Primary Care: Understanding and Supporting Clinicians' Use to Enhance Diabetes Care.
    Oser TK; Hall TL; Dickinson LM; Callen E; Carroll JK; Nease DE; Michaels L; Oser SM
    Ann Fam Med; 2022; 20(6):541-547. PubMed ID: 36443083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All Children Deserve to Be Safe, Mothers Too: Evidence and Rationale Supporting Continuous Glucose Monitoring Use in Gestational Diabetes Within the Medicaid Population.
    Levy CJ; Galindo RJ; Parkin CG; Gillis J; Argento NB
    J Diabetes Sci Technol; 2024 Sep; 18(5):1198-1207. PubMed ID: 36919680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Glucose Monitoring Adherence in Medicare Beneficiaries with Insulin-Treated Diabetes.
    Puckrein GA; Hirsch IB; Parkin CG; Taylor BT; Norman GJ; Xu L; Marrero DG
    Diabetes Technol Ther; 2023 Jan; 25(1):31-38. PubMed ID: 36409474
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Medicare Continuous Subcutaneous Insulin Infusion Policies in Patients With Type 1 Diabetes.
    Argento NB; Liu J; Hughes AS; McAuliffe-Fogarty AH
    J Diabetes Sci Technol; 2020 Mar; 14(2):257-261. PubMed ID: 30931609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes.
    Tan E; Yang W; Pang B; Dai M; Loh FE; Hogan P
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1195-202. PubMed ID: 26679968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology.
    Ravi SJ; Coakley A; Vigers T; Pyle L; Forlenza GP; Alonso T
    J Diabetes Sci Technol; 2021 May; 15(3):630-635. PubMed ID: 32172603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
    Matsuda E; Brennan P
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Characterization of Medicaid: Legacy and New Data Formats in the CMS Virtual Research Data Center.
    Williams N; Mayer CS; Huser V
    AMIA Jt Summits Transl Sci Proc; 2021; 2021():644-652. PubMed ID: 34457180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.
    Tjia J; Briesacher BA
    J Am Geriatr Soc; 2008 Oct; 56(10):1879-86. PubMed ID: 18771456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy benefit considerations for continuous glucose monitoring acquisition: Vermont Medicaid experience.
    Hurteau LB; Hogue NJ
    J Manag Care Spec Pharm; 2023 May; 29(5):550-556. PubMed ID: 37121247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMS proposes appeals process for Medicare coverage decisions.
    Patient Acc; 2002 Oct; 25(10):1, 3. PubMed ID: 12389394
    [No Abstract]   [Full Text] [Related]  

  • 19. What's in a name change?
    Hood FJ
    South Med J; 2001 Sep; 94(9):902-5. PubMed ID: 11592751
    [No Abstract]   [Full Text] [Related]  

  • 20. A Review of the First Long-term Implantable Continuous Glucose Monitoring System Available in the United States.
    Cowart K
    J Diabetes Sci Technol; 2021 Jan; 15(1):160-166. PubMed ID: 31833388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.